Abstract
BackgroundThe need for reliable clinical biomarkers to predict which patients with melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several different parameters have been considered in the past,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have